Show simple item record

dc.contributor.authorYounger, Een_US
dc.contributor.authorHusson, Oen_US
dc.contributor.authorAsare, Ben_US
dc.contributor.authorBenson, Cen_US
dc.contributor.authorJudson, Ien_US
dc.contributor.authorMiah, Aen_US
dc.contributor.authorZaidi, Sen_US
dc.contributor.authorDunlop, Aen_US
dc.contributor.authorAl-Muderis, Oen_US
dc.contributor.authorvan Houdt, WJen_US
dc.contributor.authorJones, RLen_US
dc.contributor.authorvan der Graaf, WTAen_US
dc.identifier.citationJournal of adolescent and young adult oncology, 2020en_US
dc.description.abstractPurpose: Soft tissue sarcomas (STS) account for 8% of all cancers in adolescents and young adults (AYAs). Metastatic STS contribute significantly to disease-related mortality in this age group; however, data are limited due to under-representation in clinical trials. Methods: AYAs aged 18-39 years, diagnosed with metastatic STS between 1990 and 2012, were identified from The Royal Marsden Hospital database. Outcomes of interest were clinical characteristics, treatment patterns, overall survival (OS), and prognostic factors. Results: Overall, 455 patients were included. Median age at diagnosis of metastatic STS was 33 years (interquartile range [IQR] 27-37 years). The most common histological subtypes were leiomyosarcoma (n = 68, 15%), synovial sarcoma (n = 68, 15%), Ewing sarcoma (n = 44, 10%), and rhabdomyosarcoma (n = 35, 8%). Treatments included systemic therapy (n = 395, 87%; median 2 lines [IQR 1-3]; clinical trial n = 93, 22%), radiotherapy (n = 297, 66%), and metastasectomy (n = 191, 43%). Median duration between last chemotherapy regimen and death was 4.6 months (IQR 2-10). Median OS was 19.2 months (95% confidence interval [CI] 15.8-22.2); 5-year OS was 16%. Of common subtypes, patients with rhabdomyosarcoma had the worst OS (8.8 months; 95% CI 7.9-11.4). Adverse prognostic factors included male gender, synchronous metastases, bone or liver metastases, first-line polychemotherapy, and no metastasectomy. Conclusions: Outcomes were variable; patients with supposed chemosensitive subtypes had particularly poor survival. The diverse behavior of STS in AYAs highlights the need for subtype-specific clinical trials.en_US
dc.titleMetastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center Experience.en_US
dc.typeJournal Article
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJournal of adolescent and young adult oncologyen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.embargo.termsNot knownen_US
icr.researchteamClinical and Translational Sarcomaen_US
icr.researchteamSarcoma Clinical Trialsen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorZaidi, Shane Haideren_US
dc.contributor.icrauthorHusson, Olgaen_US
dc.contributor.icrauthorJudson, Ianen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as